Simple balance test may predict cognitive decline in Alzheimer's Disease

A simple balance test may predict cognitive decline in Alzheimer's Disease, according to a study published in the March 2009 issue of the Journal of Alzheimer's Disease.

This study was carried out in 16 university hospital departments of neurology, geriatrics or psychiatry in ten cities with 686 outpatients suffering from AD. This population is representative of the AD population seen by clinicians in daily practice. Patients were evaluated by a geriatrician every six months for up to two years, and their degree of cognitive impairment was measured using the Mini Mental State Examination (MMSE). At the same time, a "one-leg balance" (OLB) test was given, where a participant was asked to stand on one leg for as long as possible. The OLB test was reported as abnormal when the participant was unable to stand on one leg for 5 seconds or more.

Participants with an abnormal OLB at baseline or/and during the follow-up showed significantly more cognitive decline at 12, 18 and 24 months than the participants with a OLB test normal at baseline and normal during the follow-up. The worst condition (having an abnormal OLB at baseline and during the follow-up= no improvement) was associated with a mean adjusted cognitive decline of 9.2 points. The best condition (having a normal OLB at baseline and during the follow-up = no worsening) was associated with a mean adjusted cognitive decline of 3.8 points.

Senior Investigator Yves Rolland, Inserm and the University of Toulouse, France, states, "Our results suggested that an abnormal OLB is a marker of more advanced dementia (worst baseline characteristic) and an independent predictor of cognitive decline in AD. Our results reinforce in an AD population, the growing evidence suggesting a link between physical performances and cognitive decline. If these results are confirmed by other data, the OLB test could be adopted in clinical practice to identify AD patients at high risk of rapid cognitive decline."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cosmochemistry techniques shed light on potential new Alzheimer's disease biomarker